Eli Lilly’s Retevmo Cuts Recurrence Risk in 151-Patient Phase 3 Lung Cancer Trial
Eli Lilly’s LIBRETTO-432 trial of Retevmo (selpercatinib) in 151 early-stage RET fusion-positive non-small cell lung cancer patients showed a highly significant reduction in disease recurrence or death. Safety profile matched prior studies and detailed results will be presented at an upcoming medical congress.
1. Phase 3 LIBRETTO-432 Topline Results
The LIBRETTO-432 Phase 3 trial randomized 151 early-stage RET fusion-positive non-small cell lung cancer patients to selpercatinib or placebo. Topline data showed a highly significant improvement in event-free survival, reflecting a notable reduction in disease recurrence or death.
2. Trial Design and Patient Cohort
This study represents the first randomized Phase 3 evaluation of a selective RET kinase inhibitor as adjuvant therapy. Patients were treated post-surgery, highlighting the potential for selpercatinib to become a standard follow-up treatment in this patient population.
3. Safety Profile and Next Steps
Safety findings remained consistent with previous trials, with no new adverse events observed. Eli Lilly plans to present detailed efficacy and safety data at an upcoming medical congress, which may inform regulatory submissions and label expansion.